May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Short Term Complications of Intravitreal Injection of Bevacizumab in Eyes With Subfoveal PED
Author Affiliations & Notes
  • O. Vidne-Hay
    Ophthalmology, Goldschleger Eye institute, Ramat Gan, Israel
  • I. Moroz
    Ophthalmology, Goldschleger Eye institute, Ramat Gan, Israel
  • R. Zolf
    Ophthalmology, Goldschleger Eye institute, Ramat Gan, Israel
  • H. Desatnik
    Ophthalmology, Goldschleger Eye institute, Ramat Gan, Israel
  • A. Alhalel
    Ophthalmology, Goldschleger Eye institute, Ramat Gan, Israel
  • J. Moisseiev
    Ophthalmology, Goldschleger Eye institute, Ramat Gan, Israel
  • Footnotes
    Commercial Relationships O. Vidne-Hay, None; I. Moroz, None; R. Zolf, None; H. Desatnik, None; A. Alhalel, None; J. Moisseiev, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1812. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      O. Vidne-Hay, I. Moroz, R. Zolf, H. Desatnik, A. Alhalel, J. Moisseiev; Short Term Complications of Intravitreal Injection of Bevacizumab in Eyes With Subfoveal PED. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1812.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To report the short term complications after intravitreal injection of Bevacizumab in eyes with subfoveal PED.

Methods:: 25 eyes of 25 patients with subfoveal PED and choroidal neovascularization underwent intravitreal injection of 1.25mg bevacizumab. Patients were followed for 6-11 months including clinical examination, optical coherence tomography and fluorescein angiography when indicated.

Results:: 5 patient developed RPE rip (5/25) and one patient developed severe submacular hemorrhage (1/25) documented both clinically and on OCT. RPE rip developed following the first injection in 3 eyes and following the 2nd injection in 2 eyes. Submacular hemorrhage developed following the 1st injection in one eye. In all eyes with these complications visual acuity decreased by 3 lines or more at the final visit. Of the 19 eyes with submacular PED and no post injection complications, visual acuity decreased in 13 eyes (13/19) and remained stable or improved in 6 eyes. In eyes that developed RPE rip the PED was large and measured 500 to 1000 micron. No cases of intraocular inflammation, elevated intraocular pressure or cataract formation were noted.

Conclusions:: Retinal pigment epithelial rip and submacular hemorrhage are potential complications of intravitreal injection of Bevacizumab although can also be the result of the natural history of the disease. These complications can severely decrease visual acuity and usually occur in eyes with large PED's. Patients should be aware of these possible complications.

Keywords: age-related macular degeneration • drug toxicity/drug effects • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×